Since 1921, when the first therapeutic peptide, insulin, was synthesized, many peptide-related accomplishments have reverberated throughout the industry, with more than 80 peptide drugs being approved ...

Second-line therapy following osimertinib in metastatic EGFR-mutated non-small cell lung cancer at an academic medical center. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.

Targeted therapies are cancer medications that work more selectively than standard chemotherapy medications. They do this by targeting specific molecules or genetic changes in cancer cells in order to ...

Modern medicine is more advanced than ever, yet clinical care still leans heavily on what is, in practice, informed guesswork. Doctors make the most probable diagnosis, select the therapy most likely ...

Immune checkpoint inhibitors (ICIs) have reshaped modern oncology, yet many solid tumors remain challenging to treat because of limited antigen visibility, extensive genetic heterogeneity, and a ...

Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group Knowledge on how molecular ...